Prelude Therapeutics IncorporatedPRLDNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank0
Studio
Year-over-Year Change

Year-over-year SG&A expense growth

Percentile
P0
Near historical low
vs 5Y Ago
-0.1x
Contraction
Streak
1 yr
Consecutive declineDecelerating
PeriodValue
2025-21.98%
2024-0.57%
2023-5.76%
202213.70%
2021154.65%
2020176.40%
201962.70%
20180.00%